查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870575

抗血栓藥物市場按藥物類別、適應症、給藥途徑和最終用戶分類－2025-2032年全球預測

Antithrombotic Drugs Market by Drug Class, Indication, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗血栓藥物市場規模將達到 688.5 億美元，年複合成長率為 6.22%。

關鍵市場統計數據
基準年 2024 424.7億美元
預計年份：2025年 451.5億美元
預測年份 2032 688.5億美元
複合年成長率 (%) 6.22%

明確闡述抗血栓治療的類型、其臨床意義以及影響臨床實務中治療決策的策略要務。

抗血栓治療涉及急診、慢性病管理和預防心臟病學等多個領域，對多種心血管和血栓性栓塞症的發生和發展產生影響。近年來，治療技術的進步促使臨床實踐轉向使用具有可預測藥物動力學的口服直接抗血栓藥物，但在手術全期和急診住院環境中，腸外給藥仍然至關重要。本文建構了一個框架，闡述了抗血栓治療的治療分類、臨床適應症和實踐環境，從而指導目前的抗血栓治療決策。

臨床實踐、商業化模式、監管監督和數位醫療服務的重大轉變正在重新定義抗血栓策略和供應動態。

抗血栓治療領域正經歷一系列交織的變革，這些變革正在重塑臨床實踐、商業模式和供應鏈結構。口服直接抗凝血劑的進步，透過提供固定劑量方案和減少監測需求，促進了部分傳統療法的臨床轉化。然而，醫院的通訊協定仍依賴腸外肝素進行急性期治療和手術全期期過渡。同時，基於腎功能評估、藥物交互作用意識增強以及逆轉劑選擇範圍擴大而日益重視的個人化治療，也使得臨床醫師教育和決策支援工具的重要性日益凸顯。

分析近期關稅政策變化如何影響抗血栓治療價值鏈的採購、生產選擇、供應和長期供應韌性。

美國在2010年代中期推出的關稅措施和貿易政策轉變產生了累積影響，波及抗血栓療法的採購、生產和下游分銷。依賴跨國活性原料藥（API）和輔料的製造商，即使核心成分的關稅有限，也因關稅分類變更及相關行政程序而面臨採購成本和前置作業時間的影響。實際上，這些調整增加了某些產品成分的到岸成本，並加劇了對單一供應來源的依賴。

透過深度細分分析，將治療領域、臨床適應症、給藥途徑和終端用戶管道連結起來，從而製定有針對性的臨床和商業策略。

嚴謹的市場區隔分析闡明了產品屬性、臨床適應症、給藥途徑和終端使用者環境如何相互作用，從而影響藥物的採納和使用。從藥物類別觀點，市場可分為抗凝血劑、抗血小板藥物和溶栓劑，其中抗凝血劑可細分為直介面服抗凝血劑（DOAC）、肝素和維生素K拮抗劑。在直介面服抗凝血劑中，市場可分為直接凝血酶抑制劑和Xa因子抑制劑，前者以Dabigatran為代表，後者以Apixaban、艾多沙班和Rivaroxaban為代表。肝素製劑分為低分子肝素和未分級肝素，二者各自發揮不同的臨床功效。

美洲、歐洲、中東和非洲以及亞太地區的區域法規結構、採購規範和醫療服務路徑如何驅動差異化的招募和供應策略

區域趨勢對全球抗血栓治療領域的臨床實務模式、管理體制、製造地和支付方策略均有顯著影響。在美洲，成熟的醫保報銷體系和口服直接抗凝血劑的廣泛應用正推動許多慢性疾病的治療模式向門診管理轉變，而醫院系統在急性腸外給藥療法的採購方面仍然擁有強大的影響力。該地區的監管流程高度重視上市後監測和真實世界數據的收集，這有望加速新型藥物的醫療保險談判和基本契約。

策略競爭格局受產品系列廣度、真實世界數據 (RWE) 的產生、供應夥伴關係附加價值服務的影響。

抗血栓治療領域的競爭動態反映了口服直接作用藥物的創新、腸外肝素的持續重要性以及抗血小板和溶栓療法在急性期治療中的長期作用之間的平衡。擁有涵蓋口服和注射的多元化產品系列的公司可以利用與醫院、零售藥局和居家醫療機構的跨通路合作關係，在整個醫療保健領域保持市場佔有率。對真實世界數據、藥物監測和病患援助計畫的策略性投資已成為影響藥品目錄定位和醫師處方偏好的關鍵差異化因素。

實現競爭優勢的可操作策略重點：證據完整性、供應彈性、通路客製化、數位化應用與支付方協作

為維持競爭優勢，產業領導者應優先考慮整合策略，兼顧臨床價值、供應鏈韌性和通路特定交付。首先，應協調進行實證項目，在最相關的適應症中，於真實世界環境中驗證療效和安全性，確保數據能夠支持與支付方、醫院處方集委員會和臨床醫生團體的對話。其次，應透過原料來源多元化、在可用地區建立生產能力以及建立二級供應商和緊急物流能力來降低供應鏈脆弱性，從而防止口服和注射產品的供應中斷。

採用透明的混合方法，結合專家訪談、監管和臨床文獻的綜合分析以及迭代式細分檢驗，確保獲得可操作的洞見。

本報告的研究結合了定性和定量證據，以確保對研究結果進行可靠的三角驗證。主要研究包括對臨床意見領袖、採購人員、醫院藥劑師和專科藥品分銷商進行結構化訪談，以了解住院和門診護理環境中的營運實踐和決策促進因素。此外，也諮詢了生產專家和監管事務負責人，以梳理供應鏈的限制和合規要求。

企業必須整合臨床、商業性和營運方面的必要因素，才能實現持續的治療價值和可靠的病患用藥途徑。

抗血栓治療管理的特點是臨床創新不斷湧現，同時營運和市場也持續複雜。口服直接作用藥物和注射用肝素的平衡、從慢性預防到急性干預的廣泛適應症，以及這些療法在各種醫療機構中的應用，共同構成了一個需要兼顧臨床價值、可靠供應和管道匹配服務的複雜局面。因此，決策者面臨雙重挑戰：他們必須證明其治療方案具有差異化的臨床療效，同時確保其生產、分銷和支付方參與策略同樣穩健有效。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大Xa因子抑制劑的應用範圍，包括周邊動脈疾病和支架置入術後血栓症形成預防。
  • 一種新型口服直接凝血酶抑制劑對心房顫動病人用藥依從性的影響
  • 引入精準醫療方法，以基於藥物基因組學分析實現個人化抗血栓治療
  • 生物類似低分子量肝素的競爭加劇，導致醫院採購價格下降。
  • 整合數位化健康監測解決方案，實現抗凝血治療的即時管理和劑量調整
  • 開發一種新型口服抗凝血劑的可逆解毒劑，可降低緊急情況下的出血風險。
  • 在患有高風險心血管疾病的患者中，雙通路抑制劑療法（低劑量抗凝血劑和抗血小板藥物聯合使用）的應用日益增多
  • 正在擴大臨床試驗計畫線，研究新型因子XI和因子XII抑制劑，旨在降低出血風險。
  • 監管改革將加快突破性抗血栓療法的核准流程，以滿足中風預防方面尚未滿足的需求。
  • 長效皮下抗凝血劑製劑的市場滲透率不斷提高，使得慢性病患者能夠減少給藥頻率。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗血栓藥物市場（依藥物類別分類）

  • 抗凝血劑
    • 直介面服抗凝血劑
      • 直接凝血酶抑制劑
      • Dabigatran
      • Xa因子抑制劑
      • Apixaban
      • 艾多沙班
      • Rivaroxaban
    • 肝素
      • 低分子量肝素
      • 未分級肝素
    • 維生素K拮抗劑
  • 抗血小板藥物
  • 溶栓藥物

第9章 依適應症分類的抗血栓藥物市場

  • 心房顫動
  • 深層靜脈栓塞症
  • 心肌梗塞
  • 肺動脈栓塞
  • 預防中風

第10章 按給藥途徑分類的抗血栓藥物市場

  • 口服
    • 藥片
  • 腸外
    • 注射

第11章 按最終用戶分類的抗血栓藥物市場

  • 居家醫療
  • 醫院
  • 零售藥房

第12章：各地區抗血栓藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 抗血栓藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國抗血栓藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Bayer Aktiengesellschaft
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • AstraZeneca PLC
    • Johnson & Johnson
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company, Limited
    • Novartis AG
    • Merck & Co., Inc.
Product Code: MRR-1A1A064C01CD

The Antithrombotic Drugs Market is projected to grow by USD 68.85 billion at a CAGR of 6.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 42.47 billion
Estimated Year [2025] USD 45.15 billion
Forecast Year [2032] USD 68.85 billion
CAGR (%) 6.22%

A clear orientation to antithrombotic therapy classes, clinical relevance, and the strategic imperatives shaping therapeutic decision-making across care settings

Antithrombotic therapies sit at the intersection of acute care, chronic disease management, and preventative cardiology, influencing outcomes across a broad spectrum of cardiovascular and thromboembolic conditions. Recent therapeutic progress has rebalanced clinical practice toward oral direct agents with predictable pharmacokinetics, while parenteral options remain essential in perioperative and acute hospital contexts. This introduction frames the therapeutic classes, clinical indications, and care settings that define contemporary decision-making in antithrombotic management.

Clinicians now weigh efficacy, safety, patient adherence, renal and hepatic considerations, and reversal strategies when selecting agents for conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke prevention. At the same time, health systems and payers evaluate total cost of care, real-world safety signals, and patient-centric delivery models, including home-based therapies and outpatient monitoring. This dynamic landscape demands integrated evidence synthesis that connects pharmacology, clinical pathways, and operational feasibility.

The remainder of this executive summary lays out transformative shifts in the therapeutic and commercial environment, examines external policy pressures such as tariff activity and supply-chain risks, and surfaces segmentation, regional, and competitive insights. Together these sections equip leaders to refine portfolio priorities, optimize distribution strategies, and align clinical value propositions with evolving payer and provider expectations.

Critical shifts in clinical practice, commercialization models, regulatory scrutiny, and digital care delivery that are redefining antithrombotic strategy and supply dynamics

The antithrombotic landscape is undergoing a set of convergent transformations that are reshaping clinical practice, commercial models, and supply-chain architecture. Advances in oral direct anticoagulants have driven a clinical pivot away from some legacy therapies by offering fixed dosing regimens and fewer monitoring requirements, yet hospital protocols continue to rely on parenteral heparins for acute management and perioperative bridging. Simultaneously, heightened emphasis on individualized therapy-driven by renal function assessment, drug-drug interaction awareness, and an expanding armamentarium of reversal agents-has elevated the importance of clinician education and decision-support tools.

On the commercial front, payers and health systems are intensifying scrutiny of total cost of ownership and real-world outcomes, prompting manufacturers to demonstrate tangible value through outcomes studies, patient support programs, and novel contracting approaches. Parallel to these forces, digital health solutions and remote monitoring are extending the continuum of care beyond traditional clinic walls, enabling safer outpatient management of chronic anticoagulation and earlier identification of adverse events. These technology-enabled care models are also catalyzing greater engagement from retail pharmacies and home-care providers in medication management and adherence initiatives.

Regulatory and quality expectations are tightening around pharmacovigilance and supply-chain transparency, while manufacturing innovations aim to reduce batch variability and improve accessibility of injectable and oral formulations. Together, these shifts require cross-functional preparedness-from clinical affairs and regulatory teams to manufacturing and commercial operations-to capture new opportunities and mitigate emerging risks.

Analysis of how recent tariff policy shifts influenced sourcing, manufacturing choices, inventory posture, and long-term supply resilience across antithrombotic value chains

Recent tariff measures and trade policy shifts introduced by the United States in the mid-decade window created a cumulative set of effects that ripple across sourcing, manufacturing, and downstream distribution for antithrombotic therapies. Manufacturers that rely on cross-border APIs and excipients saw procurement costs and lead times influenced by tariff classification changes and associated administrative duties, even when core ingredient tariffs were limited. In practice, these adjustments translated into higher landed costs for certain product components and heightened sensitivity to single-source dependencies.

In response, several supply-chain strategies have emerged. Manufacturers accelerated supplier diversification, reshored or near-shored critical stages of production, and expanded validated secondary suppliers to preserve continuity for both oral and parenteral formulations. Contract manufacturers and distributors revised procurement terms to incorporate tariff pass-through clauses, and procurement teams increased the frequency of scenario planning to model tariff-driven cost variability. Health systems and large pharmacy chains responded by tightening inventory management protocols and expanding safety stock levels for essential injectables and oral agents to avoid disruption in acute care pathways.

Regulatory compliance and customs clearance processes also became more prominent operational considerations. Firms invested in tariff classification expertise and enhanced documentation to reduce delays at ports of entry. While tariffs themselves were one element, their broader cumulative impact was to incentivize structural changes across supply networks, encouraging regional manufacturing footprints and more resilient logistics arrangements. These adaptations reduced short-term fragility but have long-term implications for unit economics, strategic sourcing, and the geographic distribution of manufacturing capacity.

Deep segmentation analysis connecting therapeutic classes, clinical indications, administration routes, and end-user channels to inform targeted clinical and commercial strategies

A rigorous segmentation lens clarifies how product attributes, clinical indications, administration routes, and end-user contexts interact to shape adoption and utilization. From a drug class perspective, the market environment is parsed across anticoagulants, antiplatelets, and thrombolytics, with the anticoagulant subset further differentiated into direct oral anticoagulants, heparins, and vitamin K antagonists. Within direct oral anticoagulants, the landscape separates direct thrombin inhibitors and factor Xa inhibitors, with dabigatran exemplifying the former and apixaban, edoxaban, and rivaroxaban representing the latter group. Heparins remain differentiated by low molecular weight formulations versus unfractionated heparin, each maintaining distinct clinical roles.

When viewed through the lens of clinical indication, therapeutic selection is influenced by characteristic risk profiles and care pathways associated with atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, and stroke prevention. Route of administration introduces further nuance: oral formulations, primarily tablets, offer adherence advantages and outpatient convenience, while parenteral options administered by injection remain central to acute management and perioperative strategies. Finally, end-user segmentation highlights divergent distribution and support requirements across home care, hospital, and retail pharmacy settings, with each channel presenting different demands for education, monitoring, and inventory management.

Overlaying these segmentation dimensions reveals practical implications for lifecycle management, clinical positioning, and commercial deployment. For example, products targeting chronic atrial fibrillation benefit from investments in adherence support and prescriber education relevant to outpatient care, whereas agents primarily used in acute pulmonary embolism or perioperative bridging require robust hospital supply assurance and clinical protocols to secure formulary adoption. Understanding these intersecting segmentation vectors enables tailored go-to-market approaches and more precise alignment of clinical evidence with channel-specific value propositions.

How regional regulatory frameworks, procurement norms, and care pathways across the Americas, Europe Middle East and Africa, and Asia Pacific drive differentiated adoption and supply strategies

Regional dynamics significantly influence clinical practice patterns, regulatory regimes, manufacturing footprints, and payer approaches across the global antithrombotic landscape. In the Americas, a mature reimbursement environment and widespread adoption of oral direct agents have shifted care models toward outpatient management for many chronic indications, while hospital systems maintain strong purchasing leverage for acute parenteral therapies. Regulatory pathways in the region emphasize post-market surveillance and real-world evidence generation, which tends to accelerate formulary dialogue and outcomes-based contracting for newer agents.

Across Europe, the Middle East & Africa, regulatory heterogeneity creates differentiated market access paths and local procurement norms, prompting manufacturers to tailor pricing, evidence, and supply strategies by jurisdiction. Centralized procurement in some territories and fragmented payer landscapes in others mean that product positioning must align with localized health economics arguments, particularly where generics and established injectables compete on cost and availability. Moreover, capacity constraints and logistic complexity in certain markets within this region heighten the importance of regional manufacturing and distribution partnerships.

The Asia-Pacific region combines rapid clinical adoption in certain high-income markets with capacity-driven opportunities in emerging economies. Rapid urbanization, expanding hospital networks, and increasing chronic disease prevalence drive demand for both oral and parenteral solutions, while regional manufacturing hubs and contract production facilities offer strategic options for cost-effective supply. Across all regions, interoperability of clinical guidelines, availability of reversal agents, and the maturity of outpatient care pathways influence the pace and nature of therapeutic uptake.

Strategic competitive patterns shaped by portfolio breadth, real-world evidence generation, supply partnerships, and value-added services that influence prescriber and payer decisions

Competitive dynamics in the antithrombotic arena reflect a balance between innovation in oral direct agents, ongoing relevance of parenteral heparins, and the enduring role of antiplatelet therapies and thrombolytics in acute settings. Companies with diversified portfolios across oral and injectable forms can leverage cross-channel relationships with hospitals, retail pharmacies, and home-care providers to sustain presence across the continuum of care. Strategic investments in real-world evidence, pharmacovigilance, and patient support programs have become critical differentiators that influence formulary positioning and prescriber preference.

Business models are adapting through greater emphasis on lifecycle management-extending indications, supporting comparative effectiveness studies, and ensuring access to reversal agents and monitoring tools. Partnerships and licensing arrangements between originators and regional manufacturers enable broader geographic coverage while preserving supply chain flexibility. Contract manufacturing organizations play a pivotal role in scaling injectable production, prompting companies to secure long-term capacity agreements and co-invest in quality assurance mechanisms to mitigate lot-to-lot variability.

Mergers, acquisitions, and strategic alliances continue to be levers for acquiring complementary capabilities, such as digital adherence platforms, specialty distribution networks, and clinical trial capacity. Firms that can integrate clinical evidence generation with robust supply assurance and channel-tailored services will be better positioned to maintain durable clinician and patient trust in a competitive therapeutic field.

Actionable strategic priorities focused on evidence alignment, supply resilience, channel customization, digital enablement, and payer collaboration to secure competitive advantage

Industry leaders should prioritize integrated strategies that address clinical value, supply resilience, and channel-specific delivery to maintain competitive advantage. First, align evidence-generation programs to demonstrate comparative clinical outcomes and safety in real-world settings for the most relevant indications, ensuring that data supports conversations with payers, hospital formulary committees, and clinician groups. Second, reduce supply-chain vulnerability by diversifying raw material sources, establishing regional manufacturing capacity where feasible, and formalizing secondary suppliers and contingency logistics to prevent service interruptions for both oral and injectable products.

Third, tailor commercial approaches to end-user contexts: invest in adherence and education programs for outpatient tablets, while ensuring rapid-response logistics, clinician training, and hospital formulary support for parenteral agents. Fourth, leverage digital health tools to support remote monitoring, dosing decision support, and patient engagement to improve adherence and reduce adverse events. Fifth, pursue collaborative contracting and risk-sharing arrangements with payers and health systems that align payments with measurable patient outcomes and real-world safety profiles.

Finally, integrate regulatory intelligence and tariff risk assessment into strategic planning to anticipate policy changes that could affect input costs and distribution timelines. By coordinating clinical, commercial, regulatory, and supply-chain initiatives, companies can create defensible positioning and responsive operational structures that support sustainable growth in a complex global market.

Transparent mixed-methods approach combining expert interviews, regulatory and clinical literature synthesis, and iterative segmentation validation to ensure actionable insights

The research underpinning this report combined qualitative and quantitative evidence streams to ensure robust, triangulated insights. Primary research included structured interviews with clinical thought leaders, procurement executives, hospital pharmacists, and specialty distributors to capture operational realities and decision drivers across inpatient and outpatient care settings. These engagements were complemented by consultations with manufacturing experts and regulatory affairs professionals to map supply-chain constraints and compliance imperatives.

Secondary research synthesized regulatory guidance, clinical trial publications, pharmacovigilance reports, and publicly available formulary determinations to contextualize primary findings and validate thematic trends. Data synthesis relied on careful cross-referencing across sources to minimize bias and to ensure that conclusions reflected consistent signals rather than isolated observations. The segmentation framework was applied iteratively, testing assumptions across drug class, indication, route of administration, and end-user scenarios to validate strategic implications.

Quality assurance protocols included peer review by domain experts and internal consistency checks to reconcile differences between stakeholder perspectives. The methodological approach emphasized transparency, reproducibility, and relevance to commercial and clinical decision-making, enabling practitioners to translate insights into tactical and strategic initiatives.

Synthesis of clinical, commercial, and operational imperatives that companies must align to deliver sustained therapeutic value and dependable access for patients

Antithrombotic therapy management is characterized by steady clinical innovation coupled with persistent operational and market complexity. The balance between oral direct agents and parenteral heparins, the multifaceted indications spanning chronic prevention to acute intervention, and the diverse care settings that deliver these therapies create a landscape in which clinical value must be matched by dependable supply and channel-aligned services. Decision-makers therefore face a dual imperative: demonstrate differentiated clinical outcomes while ensuring that manufacturing, distribution, and payer engagement strategies are equally robust.

Looking forward, organizations that integrate rigorous evidence programs with resilient supply architectures and targeted customer engagement will be best positioned to navigate regulatory shifts, tariff-driven cost pressures, and evolving care delivery models. Operational foresight-manifested in supplier diversification, regional manufacturing, and digital-enabled care pathways-will reduce exposure to external shocks while supporting sustainable access for patients. In sum, successful strategies will be those that holistically align clinical differentiation with pragmatic execution across the full product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of Factor Xa inhibitors in expanding indications such as peripheral artery disease and post-stent thrombosis prevention
  • 5.2. Impact of emerging direct thrombin inhibitors with oral formulations on patient adherence in atrial fibrillation
  • 5.3. Adoption of precision medicine approaches to tailor antithrombotic therapy based on pharmacogenomic profiling
  • 5.4. Increased competition from biosimilar low molecular weight heparins driving price erosion in hospital procurement
  • 5.5. Integration of digital health monitoring solutions for real-time anticoagulation management and dosing adjustments
  • 5.6. Development of reversible antidotes for novel oral anticoagulants to mitigate bleeding risk in emergency settings
  • 5.7. Rising use of dual pathway inhibition regimens combining low-dose anticoagulants with antiplatelet agents in high-risk cardiovascular patients
  • 5.8. Expansion of clinical trial pipelines investigating novel factor XI and XII inhibitors for lower bleeding risk profiles
  • 5.9. Regulatory shifts favoring expedited review pathways for breakthrough antithrombotic therapies to address unmet stroke prevention needs
  • 5.10. Growing market penetration of long-acting subcutaneous anticoagulant formulations enabling reduced dosing frequency in chronic care settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antithrombotic Drugs Market, by Drug Class

  • 8.1. Anticoagulants
    • 8.1.1. Direct Oral Anticoagulants
      • 8.1.1.1. Direct Thrombin Inhibitors
      • 8.1.1.1.1. Dabigatran
      • 8.1.1.2. Factor Xa Inhibitors
      • 8.1.1.2.1. Apixaban
      • 8.1.1.2.2. Edoxaban
      • 8.1.1.2.3. Rivaroxaban
    • 8.1.2. Heparins
      • 8.1.2.1. Low Molecular Weight Heparin
      • 8.1.2.2. Unfractionated Heparin
    • 8.1.3. Vitamin K Antagonists
  • 8.2. Antiplatelets
  • 8.3. Thrombolytics

9. Antithrombotic Drugs Market, by Indication

  • 9.1. Atrial Fibrillation
  • 9.2. Deep Vein Thrombosis
  • 9.3. Myocardial Infarction
  • 9.4. Pulmonary Embolism
  • 9.5. Stroke Prevention

10. Antithrombotic Drugs Market, by Route Of Administration

  • 10.1. Oral
    • 10.1.1. Tablet
  • 10.2. Parenteral
    • 10.2.1. Injection

11. Antithrombotic Drugs Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
  • 11.3. Retail Pharmacy

12. Antithrombotic Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antithrombotic Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antithrombotic Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer Aktiengesellschaft
    • 15.3.2. Pfizer Inc.
    • 15.3.3. Bristol-Myers Squibb Company
    • 15.3.4. Sanofi S.A.
    • 15.3.5. AstraZeneca PLC
    • 15.3.6. Johnson & Johnson
    • 15.3.7. Boehringer Ingelheim International GmbH
    • 15.3.8. Daiichi Sankyo Company, Limited
    • 15.3.9. Novartis AG
    • 15.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTITHROMBOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTITHROMBOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTITHROMBOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DABIGATRAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY APIXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY EDOXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RIVAROXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY UNFRACTIONATED HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTIPLATELETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY STROKE PREVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTITHROMBOTIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE ANTITHROMBOTIC DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ANTITHROMBOTIC DRUGS MARKET SIZE, BY HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ANTITHROMBOTIC D